Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...
Two studies assessed the quality and accuracy of ChatGPT recommendations for atopic dermatitis based on their concordance with clinical guidelines.
Astria Therapeutics, Inc. ( (ATXS) ) has released its Q3 earnings. Here is a breakdown of the information Astria Therapeutics, Inc. presented ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback